Pharmaceutical - ThromboGenics

Filter

Current filters:

ThromboGenics

Popular Filters

ThromboGenics to begin Jetrea study in USA

ThromboGenics to begin Jetrea study in USA

04-03-2014

Belgium-based biopharma firm ThromboGenics will soon initiate a US Phase IV study with Jetrea (ocriplasmin).

AlconBelgiumJetreaOphthalmicsPharmaceuticalResearchThromboGenics

ThromboGenics founder Désiré Collen to retire

ThromboGenics founder Désiré Collen to retire

09-12-2013

Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR: BR) has announced that Désiré Collen…

BelgiumBoardroomEuropePharmaceuticalThromboGenics

NICE issues final guidance on Jetrea

NICE issues final guidance on Jetrea

23-10-2013

NICE has published final guidance recommending Jetrea (ocriplasmin) from ThromboGenics.

EuropeJetreaOphthalmicsPharmaceuticalRegulationThromboGenics

ThromboGenics gains rights to DME drug

06-09-2013

Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR:BR) has entered into a collaboration…

Bicycle TherapeuticsBiotechnologyDiabetesLicensingOphthalmicsPharmaceuticalThromboGenics

UK's NICE recommends ThromboGenics' Jetrea for vitreomacular traction

30-08-2013

The UK's National Institute of Health and Care Excellence (NICE) has published final draft guidance recommending…

EuropeHealthcareJetreaOphthalmicsPharmaceuticalThromboGenics

Germany's IQWiG confirms Jetrea's added value for VMT patients

02-08-2013

Belgian biopharma company ThromboGenics (Euronext Brussels: THR) announced today (August 2) that the…

BiotechnologyEuropeJetreaOphthalmicsPharmaceuticalPricingRegulationThromboGenics

ThromboGenics' Jetrea gets initial NICE recommendation for VMT

12-06-2013

Belgium-based biopharma company ThromboGenics (Euronext Brussels: THR) said this morning (June 12) that…

AlconEuropeJetreaNovartisOphthalmicsPharmaceuticalPricingRegulationThromboGenics

Alcon and ThromboGenics Jetrea launched in Denmark and Sweden

28-05-2013

Belgium's ThromboGenics (Euronext Brussels: THR) says that its partner Alcon, the eye care subsidiary…

AlconEuropeJetreaMarkets & MarketingNovartisOphthalmicsPharmaceuticalThromboGenics

EU approval of Jetrea triggers a 45 million-euro milestone for ThromboGenics from Alcon

18-03-2013

The European Commission has approved Swiss drug major Novartis' (NOVN: VX) Alcon ophthalmic unit's Jetrea…

AlconEuropeFinancialJetreaNovartisOphthalmicsPharmaceuticalRegulationThromboGenics

Positive opinions for Novartis' Jetrea and Ilaris from EMA advisory panel

21-01-2013

Among a number of positive recommendations last Friday from the European Medicines Agency's Committee…

Anti-Arthritics/RheumaticsEuropeIlarisInflammatory diseasesJetreaNovartisOphthalmicsPharmaceuticalRegulationThromboGenics

ThromboGenics starts Jetrea roll-out in USA

15-01-2013

With the launch of its Jetrea (ocriplasmin) in the USA imminent, Belgian drugmaker ThromboGenics (Euronext…

BiotechnologyFinancialJetreaMarkets & MarketingOphthalmicsPharmaceuticalThromboGenics

Fujifilm Diosynth to manufacture ocriplasmin for ThromboGenics

20-11-2012

In a second major deal in less than a month, Japanese firm Fujifilm Diosynth Biotechnologies has added…

BiotechnologyFujifilm Diosynth BiotechnologiesJetreaocriplasminOphthalmicsPharmaceuticalProductionThromboGenics

US FDA approves ThromboGenics' Jetrea; advisory backing for Aegerion's lomitapide

19-10-2012

Belgian drugmaker ThromboGenics NV (Euronext Brussels: THR) yesterday received US Food and Drug Administration…

Aegerion PharmaceuticalsCardio-vascularJetrealomitapideNorth AmericaOphthalmicsPharmaceuticalRegulationThromboGenics

Ph III trials show Novartis' Jetrea improves vitreomacular traction

17-08-2012

Swiss drug major Novartis (NOVN: VX) that the New England Journal of Medicine (NEJM) this week published…

AlconJetreaNovartisocriplasminOphthalmicsPharmaceuticalResearchThromboGenics

News briefs: Priority review for ocriplasmin; Zonegran monotherapy in EU

03-07-2012

Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR) says that the US Food and Drug Administration…

EisaiEuropeNeurologicalNorth AmericaocriplasminOphthalmicsPharmaceuticalRegulationThromboGenicsZonegran

Roche returns rights to TB-403 to ThromboGenics and BioInvent, who abandon TB-402 development

05-06-2012

Belgium-based biopharma company ThromboGenics NV (Euronext Brussels: THR) and co-development partner…

BayerBioInventBiotechnologyLicensingOncologyOphthalmicsPharmaceuticalRocheTB-402TB-403ThromboGenicsXarelto

ThromboGenics re-files ocriplasmin BLA and Inspiration submits IB 1001 to FDA

17-04-2012

Belgian biopharma company ThromboGenics NV (Euronext Brussels: THR) said this morning that it has resubmitted…

BiotechnologyInspiration BiopharmaceuticalsIpsenNorth AmericaocriplasminOphthalmicsPharmaceuticalRegulationThromboGenics

Novartis unit buys rights to ThromboGenics eye drug

16-03-2012

Belgian biopharma company ThromboGenics (Euronext Brussels: THR) revealed this morning that it has entered…

AlconBiotechnologyLicensingNovartisocriplasminOphthalmicsPharmaceuticalThromboGenics

Back to top